Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus

Left Ventricular Thrombosis Clinical Trial

Official title: Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus: A Prospective Randomized Outcome Blinded Study on the Size Reduction or Resolution of Left Ventricular Thrombus

Status Completed

Clinical Trial Summary

The purpose of this study is to compare the novel oral anticoagulant apixaban with the standard therapy of warfarin on the size reduction or resolution of left ventricular thrombus over 3 months.

Clinical Trial Description

Current treatment for left ventricular thrombus is anti-coagulant or blood thinning agent known as warfarin. Recently at least three novel oral anticoagulant agents were used in the treatment of atrial fibrillation, pulmonary embolism and deep vein thrombosis (DVT). Novel oral anticoagulant drugs will require no blood taking for INR monitoring, hence less visit and more convenience to patients. Latest studies also showed lesser rate of bleeding as compared to warfarin and hence relatively safer. ;

Related Conditions & MeSH terms

• Left Ventricular Thrombosis
• Thrombosis

• NCT number: NCT02982590
• Study type: Interventional
• Source: Universiti Sains Malaysia
• Status: Completed
• Phase: Phase 3
• Start date: November 2016
• Completion date: November 2018